Therefore, aiming at the TLR4/NLRP3 pathway holds promise as a therapeutic strategy for managing ALI by attenuating the exaggerated inflammatory response and reducing lung injury. This evidence concerns the gene NLRP3 and acute respiratory distress syndrome.